JNJ stock performance?

Johnson & Johnson (JNJ) financial news, and detailed stock charts

This company symbol is outdated. Results displayed are archieved for your information

Johnson & Johnson (JNJ) Stock Summary:

Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Its Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional and over-the-counter pharmaceutical products under JOHNSON?S, AVEENO, CLEAN & CLEAR, NEUTROGENA, RoC, LUBRIDERM, LISTERINE, REACH, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC names. The company?s Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology, and virology. Its products include REMICADE, a biologic to treat Crohn?s disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and used to treat rheumatoid arthritis; TOPAMAX, for adjunctive and monotherapy use in epilepsy, as well as for treating migraines; PROCRIT that stimulates red blood cell production; RISPERDAL oral, a medication to treat the symptoms of schizophrenia, bipolar mania, and irritability associated with autistic behavior in indicated patients; RISPERDAL CONSTA, an injectable, and INVEGATM Extended-Release tablets to treat schizophrenia; LEVAQUIN and FLOXIN, anti-infective products; CONCERTA, a product for treating attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor; and DURAGESIC/Fentanyl Transdermal, a treatment for chronic pain. Johnson & Johnson?s Medical Devices and Diagnostics segment offers circulatory disease management, orthopaedic joint reconstruction and spinal care and sports medicine, surgical care and women?s health, minimally invasive surgical, blood glucose monitoring and insulin delivery, and diagnostic products, as well as disposable contact lenses. The company was founded in 1886 and is based in New Brunswick, New Jersey.
128,100 Employees
Last Reported Date: 02/21/14
Founded in 1885
Last $103.44 USD
Change Today +0.21 / 0.20%
Volume 3.5M
As of 4:15 PM 08/26/14 All times are local (Market data is delayed by at least 15 minutes).

johnson & johnson (JNJ) Snapshot

Open
$103.47
Previous Close
$103.23
Day High
$103.72
Day Low
$103.17
52 Week High
07/7/14 - $106.74
52 Week Low
10/9/13 - $85.50
Market Cap
291.7B
Average Volume 10 Days
5.5M
EPS TTM
$5.83
Shares Outstanding
2.8B
EX-Date
08/22/14
P/E TM
17.7x
Dividend
$2.80
Dividend Yield
2.63%
Request Investor Kit
JNJ:US Advanced Stock Chart

johnson & johnson (JNJ) Related Bloomberg News

Demand for Pacemakers Helps Medtronic Beat Estimates
Cubist Battling Superbugs Offers Remedy for J&J: Real M&A
Colgate Total Ingredient Linked to Hormones, Cancer Spotlights FDA Process
More Pain for Women as Cancer Limits Hysterectomy Option
SNB Trims Holdings in Apple, Exxon, J&J, SEC Filing Shows

johnson & johnson (JNJ) Related News

Whistleblower Cases Hit New Records
The Excessively Networked VC Behind SherpaVentures
Rahm Emanuel's War on Drugs
China's State Planner Fines Contacts Lens Makers, Fights Terrorism

johnson & johnson (JNJ) Key Developments

Nobel Biocare Said To Draw Interests

Nobel Biocare Holding AG (SWX:NOBN) ) that’s exploring a sale, has attracted interest from potential buyers including EQT Partners AB and Danaher Corp. (NYSE:DHR), said people with knowledge of the matter. Nobel Biocare was initially approached by EQT with an offer of about CHF 17 a share, which would have valued the company at about CHF 2.1 billion said the people, who asked not to be identified because talks are private. The offer prompted Nobel Biocare and its adviser Goldman Sachs Group Inc. (GS) to invite other bids as it seeks a higher price, the people said. Other companies such as DENTSPLY International Inc. (NasdaqGS:XRAY) and buyout firms are also expected to look at Nobel Biocare, the people said. Potential buyers include Straumann Holding AG (SWX:STMN), Sirona Dental Systems Inc., Johnson & Johnson (NYSE:JNJ), Medtronic, Inc. (NYSE:MDT), Zimmer Holdings, Inc. (NYSE:ZMH), Henry Schein, Inc. (NasdaqGS:HSIC), and 3M Company (NYSE:MMM), according to a note on July 30 from Lisa Bedell Clive, a London-based analyst at Sanford C. Bernstein & Co. Nobel Biocare could sell for as much as CHF 18 a share, she said in the note.

Johnson & Johnson Announces Dividend for the Third Quarter of 2014, Payable on September 9, 2014

NEW Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the third quarter of 2014 of $0.70 per share on the company's common stock. The dividend is payable on September 9, 2014 to shareholders of record at the close of business on August 26, 2014. The ex-dividend date is August 22, 2014.

Johnson & Johnson Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months of 2014; Provides Earnings Guidance for the Full Year of 2014

Johnson & Johnson announced unaudited consolidated earnings results for the second quarter and six months of 2014. For the quarter, the company reported sales to customers of $19,495 million against $17,877 million a year ago. Earnings before provision for taxes on income were $5,626 million against $4,793 million a year ago. Net earnings were $4,326 million against $3,833 million a year ago. Diluted net earnings per share were $1.51 against $1.33 a year ago. Adjusted earnings before provision for taxes on income were $6,050 million against $5,359 million a year ago. Adjusted net earnings were $4,775 million against $4,289 million a year ago. Adjusted diluted net earnings per share were $1.66 against $1.48 a year ago. For the six months, the company reported sales to customers of $37,610 million against $35,382 million a year ago. Earnings before provision for taxes on income were $11,050 million against $9,054 million a year ago. Net earnings were $9,053 million against $7,330 million a year ago. Diluted net earnings per share were $3.15 against $2.55 a year ago. Adjusted earnings before provision for taxes on income were $11,610 million against $10,429 million a year ago. Adjusted net earnings were $9,201 million against $8,396 million a year ago. Adjusted diluted net earnings per share were $3.20 against $2.92 a year ago. The company increased its earnings guidance for full-year of 2014 to $5.85 to $5.92 per share. The company's guidance excludes the impact of special items.

Johnson & Johnson financial resources

otc, otcbb, pinksheet, JNJ, ob Johnson & Johnson
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ:US $103.44 USD +0.21

JNJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
International Business Machines Corp $192.99 USD +1.83
Novartis AG SFr.82.20 CHF +0.50
Pfizer Inc $29.21 USD +0.30
Roche Holding AG SFr.269.40 CHF +1.70
Procter & Gamble Co/The $83.38 USD -0.16
 

Industry Analysis

JNJ

Industry Average

Valuation JNJ Industry Range
Price/Earnings 19.1x
Price/Sales 4.0x
Price/Book 3.7x
Price/Cash Flow 18.7x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Archieved Financial News About Johnson & Johnson

Drugmakers Seek End or Changes to U.S. Medication Naming Rules

Quote:
Read article

J&J Recall Watch: Tylenol Cold Gelcaps Pulled

Quote:
Read article

Is Donald Trump Buying Bank of America?

Keywords: Is Donald Trump Buying Bank of America?, intc,bac,blk,c,cat,dia,gld,jnj,pg
Quote:  I love real estate, but good real estate is very hard to get.”  Donald Trump explained that he bought stock in  Bank of America , Citigroup, Caterpillar, Intel, Johnson & Johnson, and Procter & Gamble.  Donald Trump also said, “I love these companies.  I’ve watched them for years and I’ve never owned stock in them.  I went out yesterday and said, look I’m not getting interest on CDs, so I went out and bought some stock.” Investors should ...
Read article

Best in Breed Dividend Stocks: Portfolio Check Up

Quote:
Read article

Warren Buffett's Top 6 High-Yield Stocks: Beating the Broader Market So Far in 2011

Quote:
Read article

Johnson & Johnson poised to outperform during recession, says Wells Fargo

Quote: theflyonthewall.com: Massachusetts AG sues Ortho-Mcneil over Risperdal marketingDrug manufacturer Ortho-McNeil-Janssen, a subsidiary of Johnson & Johnson, is being sued by the Attorney General of Massachusetts for illegally marketing Risperdal, an atypical antipsychotic medication. The lawsuit alleges that Janssen promoted the drug to treat elderly dementia and a number of uses in children and adolescents when these uses had not been shown to be safe and effective and had not been approved by t...
Read article

JOHNSON & JOHNSON Files SEC form 10-Q, Quarterly Report

Quote:
Read article

J&J Tentatively Agrees to Settle Risperdal Criminal Charge

Quote:
Read article

If Fed Is Out of Bullets, Are Tax Cuts Only Option?

Keywords: Washington,United States,Treasurys,Treasury Department,Republicans,Political Leaders,Politics and Government,North America,Euro;EUR=X,Federal Budget (U.S.),Economy (U.S.),Democrats,Deficits,Debt,Currencies,Congress,Barack Obama,Bonds,Banking,Federal Reser
Quote:
Read article

Johnson & Johnson: A Regal Dividend Stock Going Cheap

Quote:
Read article

3 Dividend Powerhouses Selling at a Discount

Quote:
Read article

Cramer's Watch List After Monday's Market Bloodbath

Quote:
Read article

US approval of Roche melanoma drug may come early

Quote:
Read article

S&P rating: Potential knock-on effects of downgrade

Keywords: S&P rating, downgrade, AAA, debt, debt ceiling, AA+, debt ceiling, debt rating, credit rating, debt, deficits,
Quote:
Read article

A Look at Warren Buffett's 5 Best Bargain Stocks

Quote:
Read article

Nexgen Artificial Knee Suits Targeting Zimmer Haunt Lawyers Seeking Payout

Quote:
Read article

UPDATE 1-IFR-30-year debt too good to refuse with UST below 4%

Keywords: Ciara Linnane
Quote:
Read article

RPT-UPDATE 1-Bayer rival Boehringer gets EU nod for Pradaxa pill

Keywords: United States
Quote:
Read article

The 'Hold Forever Portfolio' Fallacy

Quote:
Read article

UPDATE 3-Pfizer global drug sales fall, spark concern

Keywords: United States, Dave Zimmerman, Matthew Lewis, Michele Gershberg
Quote:
Read article

You can still leave a comment about Johnson & Johnson JNJ

Besides Johnson & Johnson's Stock there is more great Microcap and Stock Market information available at Realpennies.com